AVO.L Regulatory News (AVO)

18 November 2014

ADVANCED ONCOTHERAPY Plc

("Advanced Oncotherapy" or the "Company")

Investor presentation

Advanced Oncotherapy (AIM: AVO), the developer of next generation proton therapy systems for cancer treatment, announces that, further to the RNS Reach on 30 October 2014, it will be hosting an investor and analyst presentation today at 4pm at the Royal Society of Medicine, London.

The presentation will outline Advanced Oncotherapy's strategy, offer further technical information on this next generation proton therapy system and its main components, provide a summary of expected key milestones for the development of the LIGHT system, and will provide some illustrative financial information.

No new material information will be disclosed outside of this presentation and the presentation will be available on the Company's website (see below) this afternoon to coincide with the start of the meeting.

For the presentation please visit: http://www.avoplc.com/Investors/Results-reports-and-presentations

For further information contact:

About Advanced Oncotherapy Plc www.avoplc.com

Advanced Oncotherapy's team based at CERN in Geneva focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. As a result, Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.